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Abstract Tofacitinib is an oral Janus kinase inhibitor for the
treatment of rheumatoid arthritis (RA). This post hoc analysis
investigated the effect of methotrexate (MTX) dose on the
efficacy of tofacitinib in patients with RA. ORAL Scan
(NCT00847613) was a 2-year, randomized, Phase 3 trial eval-
uating tofacitinib in MTX-inadequate responder (IR) patients
with RA. Patients received tofacitinib 5 or 10 mg twice daily
(BID), or placebo, with low (≤12.5 mg/week), moderate
(>12.5 to <17.5 mg/week), or high (≥17.5 mg/week) stable
background MTX. Efficacy endpoints (at months 3 and 6)
included American College of Rheumatology (ACR)
20/50/70 response rates, and mean change from baseline in
Clinical Disease Activity Index (CDAI), Disease Activity
Score in 28 joints (DAS28)–4(erythrocyte sedimentation rate
[ESR]), Health Assessment Questionnaire-Disability Index
(HAQ-DI), and modified Total Sharp score. 797 patients were
treated with tofacitinib 5 mg BID (N = 321), tofacitinib 10 mg
BID (N = 316), or placebo (N = 160); 242, 333, and 222
patients received low, moderate, and high MTX doses,
respectively. At months 3 and 6, ACR20/50/70 response rates
were greater for both tofacitinib doses vs placebo across all
MTX doses. At month 3, mean changes from baseline in
CDAI and HAQ-DI were significantly greater for both
tofacitinib doses vs placebo, irrespective of MTX category;
improvements were maintained at month 6. Both tofacitinib
doses demonstrated improvements in DAS28–4(ESR), and
less structural progression vs placebo, across MTX doses at
month 6. Tofacitinib plus MTX showed greater clinical and
radiographic efficacy than placebo in MTX-IR patients with
RA, regardless of MTX dose.
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Introduction
Current guidelines advise that treatment of rheumatoid arthri-
tis (RA) should be initiated with conventional synthetic
disease-modifying antirheumatic drugs (csDMARDs), such
asmethotrexate (MTX). For patients with inadequate response
(IR) to csDMARDs, options include biologic DMARDs
(bDMARDs), such as tumor necrosis factor inhibitors
(TNFi), or targeted synthetic small-molecule DMARDs
(tsDMARDs), often given in combination with csDMARDs
[1, 2].
Early intervention with csDMARDs, usually MTX, has
been shown to be beneficial in achieving a good clinical response
in a proportion of patients, with resulting modification of the
course of the disease [1, 3, 4]. However, not all patients
achieve remission with MTX. There is extensive evidence to
suggest that concomitant use of a bDMARD with MTX is
beneficial in achieving treatment goals [5–12]. However, it
is not clear whether there is a minimum or maximum dose
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of MTX that, when given in combination with bDMARDs,
can affect clinical outcomes. Recently, a study has shown that
increasing doses of MTX administered concomitantly with
adalimumab broadly associated with an increasing proportion
of patients achieving clinical efficacy endpoints [13, 14]. A
recent study in Japan has also shown that adalimumab plus
≥10 mg MTX consistently resulted in better improvement in
disease activity score in 28 joints (DAS28) and more patients
with DAS28-defined remission compared with adalimumab
plus MTX <10 mg [15].
Tofacitinib is an oral Janus kinase inhibitor for the treat-
ment of RA. The efficacy and safety of tofacitinib 5 and 10mg
twice daily (BID), as monotherapy or in combination with
csDMARDs, have been demonstrated in Phase 2 and
Phase 3 clinical trials and in long-term extension studies
[16–27]. The tofacitinib clinical development program includ-
ed both MTX-naïve patients and those with an IR to treatment
with DMARDs, including csDMARDs (primarily MTX) and
TNFi.
ORAL Scan (NCT00847613) was a Phase 3 clinical trial
that investigated tofacitinib 5 and 10 mg BID vs placebo, all
with stable background MTX, in MTX-IR patients with RA
[24]. In ORAL Scan, tofacitinib plusMTX improved the signs
and symptoms of RA, clinical disease activity, and reduced the
progression of structural damage compared with placebo plus
MTX at month 6. The structural damage results were statisti-
cally significant with tofacitinib 10 mg BID (p < 0.05), but not
with tofacitinib 5 mg BID (p = 0.0792) [24].
This post hoc analysis of data from ORAL Scan investigat-
ed whether there was a difference in the benefit of tofacitinib
when given with oral MTX at different dose ranges.
Materials and methods
Study design, patients, and MTX dose categories
ORAL Scan (NCT00847613) was a 2-year, multinational,
randomized, double-blind, parallel-group, placebo-controlled
Phase 3 clinical trial conducted in accordance with the
Declaration of Helsinki and International Conference on
Harmonisation Guidelines for Good Clinical Practice. The
Institutional Review Board at each study center approved
the protocol and all patients provided written informed
consent.
Details of the study design and patient population have
been reported previously [24]. Briefly, eligible patients were
aged ≥18 years with active RA despite receiving MTX at a
stable dose of 15–25 mg/week for ≥6 weeks (MTX doses
<15 mg/week were permitted if there were safety issues at
higher doses, but dose adjustments were not permitted during
the study). Patients were randomized 4:4:1:1 to receive
tofacitinib 5 mg BID, tofacitinib 10 mg BID, placebo
advanced to tofacitinib 5 mg BID, or placebo advanced to
tofacitinib 10 mg BID, all in combination with MTX.
Placebo patients advanced to active treatment at month 3 if
they did not meet a pre-defined response of ≥20 % improve-
ment in swollen and tender joint counts. All remaining place-
bo patients mandatorily advanced to their assigned tofacitinib
dose at month 6 regardless of clinical response.
In this post hoc analysis, patients were divided into
three categories according to their baseline mean weekly
MTX dose: low (≤12.5 mg/week), moderate (>12.5 to
<17.5 mg/week), and high (≥17.5 mg/week). MTX
doses were stable throughout the study as per protocol.
Efficacy assessments
Signs and symptoms and clinical disease activity were
assessed at months 3 and 6 utilizing American College of
Rheumatology 20, 50, and 70 % response rates
(ACR20/50/70), least squares mean (LSM) change from
baseline in Clinical Disease Activity Index (CDAI) score,
and the proportion of patients achieving low disease activity
(CDAI score ≤10) and remission (CDAI score ≤2.8). LSM
change from baseline in DAS28–4(erythrocyte sedimentation
rate [ESR]) was assessed at month 6.
Functional status was assessed by LSM change from base-
line in the Health Assessment Questionnaire-Disability Index
(HAQ-DI) score, including the proportion of patients achiev-
ing HAQ-DI <0.5.
Radiographic progression was assessed via LSM change
from baseline in van der Heijde modified Total Sharp Score
(mTSS), and the proportion of patients with no radiographic
progression, defined as ≤0.5-unit increase from baseline in
mTSS at month 6.
Statistical analyses
In this exploratory, post hoc analysis, the primary analysis
population was the Full Analysis Set, which included all ran-
domized patients who received ≥1 dose of study medication
and had ≥1 post-baseline measurement. To handle missing
data, no imputation was applied to descriptive statistics of
patient demographics and baseline characteristics. For binary
efficacy endpoints, non-responder imputation (NRI) was ap-
plied. In particular, patients who withdrew from a study for
any reason before month 6, or patients who advanced treat-
ment to active tofacitinib after month 3, had their values on or
after withdrawing or advancing treatment set to Bnon-
responder^ in the efficacy analyses. Longitudinal continuous
variables were analyzed using a mixed-effect repeated mea-
sure model with no imputation for missing data. The fixed
effects of treatment, visit, and treatment-by-visit interaction
were included, with subject as a random effect.
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This was a post hoc analysis, and no adjustment was made
for multiple testing. For the efficacy analyses, 95 % confi-
dence intervals (CIs) for each tofacitinib group vs placebo
were calculated in each MTX dose category; a CI that did
not contain 0 was taken to indicate that the difference between
tofacitinib and placebo was significant. Logistic regression
analyses for binary variables and linear regression analyses
for continuous variables were used to evaluate the effect of
various baseline factors (CDAI, DAS28–4[ESR], HAQ-DI,
body mass index [BMI], glucocorticoid [GC] use, MTX dose,
swollen joints, and tender joints) on efficacy responses. A
multivariate model was developed that incorporated variables
from a univariate model with p values <0.10 and removed
factors using stepwise, backward, and forward methods until
only significant factors remained (p < 0.05).
Results
Patients
A total of 797 patients were randomized to receive tofacitinib
5 mg BID (N = 321), tofacitinib 10 mg BID (N = 316), or
placebo (N = 160), all in combination with backgroundMTX;
patients continued to receive concomitant MTX at the dose
they were receiving at study start. The number of patients in
the low, moderate, and high MTX dose categories was 242
(30 %), 333 (42 %), and 222 (28 %), respectively (Table 1).
The mean weekly MTX dose in the three categories was 9.4,
15.0, and 20.9 mg/week, respectively (Table 1).
Baseline demographics and disease characteristics were
generally similar across the MTX dose categories. BMI, pro-
portion of Caucasian patients, GC use, swollen and tender
joint counts, and CDAI scores tended to be higher among
patients in the high MTX dose category, and proportion of
patients with prior TNFi therapy, which tended to be higher
in the low MTX dose category (Table 1).
Efficacy
Clinical and functional outcomes
The proportion of patients achieving ACR20/50/70 response
rates was significantly greater for those receiving tofacitinib 5
and 10 mg BID vs placebo, regardless of MTX dose level, at
both month 3 and month 6. The only exception was ACR70
for tofacitinib 5 mg BID at month 3 in the moderate MTX
dose group, which was numerically greater than placebo
(Fig. 1).
Tofacitinib 5 and 10 mg BID-treated patients achieved sig-
nificantly greater reductions from baseline in CDAI scores at
month 3, compared with placebo, irrespective of MTX dose
(Fig. 2a). Other than the tofacitinib 5 mg BID vs placebo
comparison in the highMTX dose group, significant improve-
ments in CDAI scores (Fig. 2b) and DAS28–4(ESR) scores
(Table 2) were maintained at month 6 in all three MTX dose
categories.
At month 6, significantly higher proportions of patients
treated with both doses of tofacitinib achieved CDAI low
disease activity (CDAI score ≤10) and remission (CDAI
score ≤2.8) compared with the placebo group, regardless of
background MTX dose, with the exception of the tofacitinib
5 mg group with low-dose MTX for CDAI remission
(Table 2).
Improvements from baseline in HAQ-DI were significantly
greater for tofacitinib 5 and 10 mg BID vs placebo in all MTX
dose groups at months 3 and 6, other than tofacitinib 5 mg
BID in the high-dose MTX group at month 6 (Fig. 2c, d). At
month 6, significantly higher proportions of patients treated
with tofacitinib 5 and 10 mg BID vs placebo in all MTX dose
groups achieved HAQ-DI <0.5, except for tofacitinib 5 mg
BID in the high-dose MTX group (Table 2).
Radiographic progression
No clear relationship between radiographic progression (as
measured by LSM change from baseline in mTSS scores
and the proportion of patients with no radiographic progres-
sion) and MTX dose was observed at month 6 with tofacitinib
5 or 10 mg BID (Fig. 3a, b). Generally, less radiographic
progression was observed with both tofacitinib 5 and 10 mg
BID plusMTX compared with placebo plusMTX (Fig. 3a, b).
In the placebo-treated patients, less radiographic progression
was demonstrated in the moderate and highMTX dose groups
compared with the low MTX dose group (Fig. 3a).
Efficacy analyses by MTX dose and baseline variables
The univariate and multivariate regression analyses performed
to assess the effect of baseline variables on efficacy outcomes
showed no significant effect of BMI, GC use, orMTX dose on
disease activity assessments with either tofacitinib 5 or 10 mg
BID (Supplementary Table 1 in Online Resource 1).
Discussion
It has been shown that the concomitant use of a bDMARD
with MTX can be clinically beneficial in MTX-IR patients;
what has not been demonstrated conclusively is whether
there is a minimum dose of MTX that, when given in com-
bination with bDMARDs, affects clinical outcomes. In a
previous post hoc analysis of data from the tofacitinib clin-
ical RA program, broadly similar efficacy was seen in stud-
ies with tofacitinib administered as monotherapy and
tofacitinib given in combination with MTX [28].
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Whereas the earlier analysis used data from four different
clinical studies, this post hoc analysis of data from the
Phase 3 ORAL Scan study was performed to establish
whether the efficacy of tofacitinib 5 mg BID or 10 mg
BID is affected by the dose of concomitant MTX within
a single study. The MTX-IR population for this post hoc
analysis was similar to MTX-IR patients with RA who are
candidates for tofacitinib or bDMARDs in clinical
Fig. 1 Proportion of patients achieving a ACR20, b ACR50, and
c ACR70 at month 3 and month 6. *p < 0.05 vs placebo plus MTX.
ACR American College of Rheumatology, BID twice daily,
CI confidence interval, MTX methotrexate, n number of patients
responding, N number of patients assessed, wk week
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Fig. 2 Change from baseline in a CDAI at month 3, b CDAI at month 6,
cHAQ-DI at month 3, and dHAQ-DI at month 6. *p < 0.05, **p < 0.001,
***p < 0.0001 vs placebo; Full Analysis Set. BID twice daily,
CDAI Clinical Disease Activity Index, CFB change from baseline,
HAQ-DI Health Assessment Questionnaire-Disability Index, LSM least
squares mean, MTX methotrexate, N number of patients assessed,
SE standard error, wk week
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practice. The finding of whether there is a dose-dependent
effect of concomitant MTX on clinical efficacy with
tofacitinib is therefore clinically relevant.
Analysis of data from the ORAL Scan study revealed that
both tofacitinib 5 and 10 mg BID were more effective in
improving clinical activity and functional status in RA pa-
tients compared with placebo, regardless of the background
MTX dose. The proportion of patients achieving ACR20/50/
70 response rates, CDAI LDA ≤10, CDAI remission ≤2.8, and
HAQ-DI <0.5 from baseline were greater for both tofacitinib
doses compared with placebo, regardless of MTX dose level.
Improvements from baseline in HAQ-DI, CDAI, and
DAS28–4(ESR) were greater for both tofacitinib doses plus
MTX compared with placebo plus MTX, regardless of MTX
dose level.
Generally, less radiographic progression was observed at
month 6 with both tofacitinib doses plus MTX compared
with placebo plus MTX; the inhibition of radiographic pro-
gression at month 6 with either dose of tofacitinib did not
appear to be MTX dose-dependent. In this post hoc analy-
sis, tofacitinib 5 mg BID plus MTX showed significantly
lower radiographic progression vs placebo plus MTX at
month 6 in the low and high MTX dose groups, but a sig-
nificant difference was not observed in the overall analysis
[24]. In general, as expected, at month 6, higher doses of
MTX in the placebo-treated patients with background
MTX achieved improved clinical response and improved
functional status with less radiographic progression than
the lowest dose of MTX.
Concomitant use of MTX with all currently approved
bDMARDs has consistently been associated with better effi-
cacy than bDMARD monotherapy, but studies examining the
effect of MTX dose on the efficacy of bDMARDs have re-
ported differing findings. In a trial of MTX- and bDMARD-
naïve patients treated with adalimumab 40 mg every other
week in combination with MTX (2.5, 5, 10, or 20 mg per
week), a trend of increased efficacy with increasing MTX
dose was noted; however, the efficacy of adalimumab plus
10 or 20 mg of MTX weekly appeared equivalent [13].
Similar results were reported in the Dutch RhEumatoid
Arthritis Monitoring (DREAM) registry [14]. In this report,
there did not appear to be a difference in efficacy of
adalimumab, etanercept, or infliximab in patients receiving
10, 15, 20, or 25 mg/week concomitant MTX. In the
MUSICA trial, in which patients were treated with
adalimumab 40 mg every other week in combination with
low- or high-dose MTX (7.5 or 20 mg per week), small dif-
ferences in terms of efficacy were observed between the two
MTX groups but higher responses and some significant dif-
ferences were reported with high-dose MTX [29]. In another
study, a sub-analysis of pooled Phase 3 data of certolizumab
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It has been postulated that the mechanism for the increased
efficacy of bDMARDs, especially monoclonal antibodies,
with concomitant MTX vs bDMARD monotherapy is the im-
pact of MTX on serum levels of bDMARDs. A study on the
concentration-effect curve of adalimumab demonstrated that
concomitant administration of MTX was associated with sig-
nificantly higher trough levels of adalimumab compared with
adalimumabmonotherapy; the median level with concomitant
MTX use was within the range of adalimumab concentrations
thought necessary for clinical efficacy [31]. One mechanism
of clearance of adalimumab from serum is related to the pro-
duction of antidrug antibodies (ADAb) [31], with patients
producing higher amounts of ADAb having reduced serum
concentrations of functional adalimumab [32]. MTX, an im-
munomodulator, has been shown to reduce the immunogenic-
ity of adalimumab in a dose-dependent manner [33]. An in-
vestigation of the co-administration of MTX 15–25 mg/week
with tofacitinib in patients with RA reported no clinically
significant effect on the pharmacokinetic profile of either drug
[34].
Limitations of this post hoc analysis include low patient
numbers in some treatment groups. The analysis could not
determine definitively whether there is a differential effect of
tofacitinib plus MTX depending on MTX dose. There were
also some differences between groups in baseline characteris-
tics, although these did not appear to affect efficacy assess-
ments and interpretation. In the present analysis, patients had
to have active disease despite treatment with MTX for inclu-
sion in the study and therefore had limited response to MTX,
irrespective of the dose. However, the majority of patients
responded when tofacitinib was added to MTX. To determine
the effect of MTX dose on the efficacy of tofacitinib, a study
that includes csDMARD-, bDMARD-, and ts-DMARD-naïve
patients assigned to varying doses of MTX plus concomitant
Fig. 3 Radiographic progression
at month 6 by MTX dose
category: a LSM change from
baseline in mTSS and b
proportion of patients with no
radiographic progression (mTSS
≤0.5). *p < 0.05 vs placebo;
aNon-responder imputation; Full
Analysis Set. BID twice daily,
CFB change from baseline, CI
confidence interval, LSM least
squares mean, mTSS modified
Total Sharp/van der Heijde Score,
MTX methotrexate, SE standard
error, wk week
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tofacitinib or MTX monotherapy is required, similar to the
study conducted byBurmester and colleagues for adalimumab
[13]. Such a study could show unequivocally whether there is
a dose response of MTX on tofacitinib efficacy, together with
information on any differences in safety with increasingMTX
dose.
In conclusion, this post hoc analysis confirms the main
findings from ORAL Scan. Tofacitinib plus MTX generally
showed greater clinical and radiographic efficacy than placebo
plus MTX in MTX-IR patients with RA. The findings report-
ed here suggest that in this population, the effect of tofacitinib
is irrespective of background MTX dose, and that concomi-
tant high-dose MTX may not be needed for tofacitinib
efficacy.
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